IKZF3 and systemic lupus erythematosus: CC-220 (iberdomide) (Figure 1G) has stronger Aiolos/Ikalos degradation activity than IMiDs and is being studied for the treatment of systemic lupus erythematosus (SLE) [106,107,108].